Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis (Nasdaq: OCS) announced a positive meeting with the FDA and is launching the PIONEER program to advance Privosegtor into registrational trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company plans three pivotal studies: PIONEER-1 (Q4 2025), PIONEER-2 (1H 2026), and PIONEER-3 (mid-2026). Primary endpoint: low-contrast visual acuity (LCVA) at 3 months, with dosing/enrollment mirroring the positive Phase 2 ACUITY trial. Oculis reported preliminary cash, cash equivalents and short-term investments of ~$182 million, with runway expected into 2H 2027. Full Q3 2025 results are planned for November 10, 2025.
Oculis (NASDAQ:OCS) has announced that a Person Discharging Managerial Responsibilities (PDMR) has executed trades in accordance with a pre-established Rule 10b5-1 trading plan. The transactions were conducted under the Securities Exchange Act of 1934 guidelines, demonstrating compliance with regulatory requirements for insider trading.
Oculis (NASDAQ: OCS) announced upcoming presentation of positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis at ECTRIMS 2025 Congress. The trial demonstrated clinically meaningful improvements in vision with 18 letters at 3 months, preservation of retinal structure, and a favorable safety profile.
The presentation, scheduled for September 24, 2025, will be delivered by Dr. Céline Louapre from Pitié-Salpêtrière Hospital. The study showed promising neuroprotective effects, including preservation of retinal ganglion cells and significant improvements in low contrast visual acuity, highlighting potential applications in multiple sclerosis relapses and other neuro-ophthalmic conditions.
Oculis (NASDAQ:OCS) has announced the vesting and settlement of Restricted Stock Units (RSUs) for several company directors. The notifications concern RSU settlements for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.
Oculis (Nasdaq: OCS) and EURETINA have announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, which honors exceptional postgraduate scholars in retina research. The award, established in 2024, commemorates Professor Ramin Tadayoni, Oculis' former Chief Scientific Officer.
Dr. Ramtohul, an attending physician at Aix-Marseille University Hospital and Ph.D. candidate, is recognized for his contributions to retinal imaging and diseases, with 111 peer-reviewed publications. His research focuses on cellular mechanisms of amblyopia and retinal disease pathophysiology through multimodal imaging analysis.
Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for director Arshad Khanani. The RSUs were previously granted as part of the company's equity compensation program.
Oculis (NASDAQ: OCS) announced upcoming presentations of clinical trial results at multiple ophthalmology conferences in September 2025. Key highlights include:
The company will present expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME), focusing on subgroups by lens status and prior treatment status. Additionally, Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis will be presented in EURETINA's late-breaking session, showing clinically meaningful visual function improvement with anatomical neuroprotection benefits.
Presentations will take place at the Ophthalmology Futures Retina Forum, EURETINA Innovation Spotlight, 25th EURETINA Congress, and Retina Society Annual Congress.
Oculis (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, announced its participation in five major investor conferences during September 2025.
Key presentations include:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston)
- H.C. Wainwright Global Investment Conference (Sept 8-10, New York) - Fireside chat on Sept 8 at 2:30 PM ET
- Baird Global Healthcare Conference (Sept 9-10, New York) - Company update on Sept 9 at 3:45 PM ET
- Pareto Securities Healthcare Conference (Sept 16, Stockholm) - Update at 9:15 AM CET
- Leerink Partners Biopharma Summit (Sept 17-19, Healdsburg)
Oculis (NASDAQ: OCS) has appointed two distinguished medical experts as Chief Medical Advisors. Dr. Mark Kupersmith joins as Chief Medical Advisor for Neuro-Ophthalmology, while Dr. Sebastian Wolf becomes Chief Medical Advisor for Ophthalmology.
The appointments follow significant pipeline progress, including completed enrollment in Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema and positive Phase 2 ACUITY results for Privosegtor (OCS-05) in acute optic neuritis. The company also aligned with FDA on the first genotype-based development program in ophthalmology with Licaminlimab (OCS-02) for dry eye disease.
Topline results for the DIAMOND trials are expected in Q2 2026, with NDA filing planned for 2H 2026.
Oculis (NASDAQ: OCS) reported Q2 2025 financial results and provided updates on its ophthalmology pipeline. The company maintained a cash position of $201.3 million as of June 30, 2025, with runway into early 2028, supplemented by a $123.7 million BlackRock loan facility.
Key pipeline developments include: OCS-01's Phase 3 DIAMOND trials completion of enrollment with over 800 patients for diabetic macular edema treatment, with topline results expected Q2 2026; Privosegtor (OCS-05) advancing to Phase 2/3 trial in acute optic neuritis in 1H 2026 following positive Phase 2 results; and Licaminlimab (OCS-02) preparing for genotype-based Phase 2/3 trial in dry eye disease in 2H 2025.
Financial results showed R&D expenses of $18.1 million for Q2 2025, slightly down from Q2 2024, and a year-to-date net loss of $67.9 million, increased from $41.5 million in the same period 2024.
FAQ
What is the current stock price of Oculis Holding (OCS)?
What is the market cap of Oculis Holding (OCS)?
